Where does Travere Therapeutics, Inc.'s cash flow data come from?

Every line is extracted from Travere Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	——	——	-$88.54M+47.6%	-$169.06M+25.4%	-$226.71M+29.5%
Depreciation and amortization	$73.15M+20.4%	$60.74M+11.1%	$54.7M+9.1%	$50.15M+7.9%	$46.48M+6.7%
Stock-based compensation	$49.52M+10.4%	$44.87M+5.3%	$42.62M+8.2%	$39.38M+1.9%	$38.65M+4.7%
Change in accounts receivable	——	——	$57.63M+306%	$14.2M+21.8%	$11.66M+94.3%
Change in inventories	-$629K+87.5%	-$5.04M-40.9%	-$3.57M-14.0%	-$3.13M-82.5%	-$1.72M-146%
Change in accounts payable	——	——	——	——	——
Change in accrued liabilities	$17.48M-39.4%	$28.84M—	——	——	——
Change in other assets	$12.82M+58.1%	$8.1M—	——	——	——
Change in other liabilities	-$8.47M+12.7%	-$9.7M-15.8%	-$8.37M—	——	——
Other working capital changes	——	——	——	——	-$6.34M+23.4%
Change in deferred revenue	——	——	——	-$5.29M+11.0%	-$5.94M+2.8%
Net cash from operating activities	——	——	——	——	-$160.66M+32.3%
Proceeds from maturities/sales of investments	$319.22M-1.4%	$323.6M+9.2%	$296.22M+21.4%	$243.92M-9.0%	$268.13M-17.8%
Purchases of intangible assets	$68.55M+17.9%	$58.16M+19.8%	$48.56M+16.4%	$41.71M+0.4%	$41.53M+14.7%
Net cash from investing activities	——	——	——	——	——
Proceeds from issuance of common stock	$486K—	$0-100%	$142.96M+2.5%	$139.44M+0.3%	$138.98M+3.1%
Net cash from financing activities	——	——	$78.97M-45.3%	$144.36M+0.5%	$143.67M+3.0%
Effect of exchange rate changes on cash	——	——	$1.74M-12.4%	$1.99M+2,858%	-$72K+92.1%
Net increase (decrease) in cash	——	——	$74.52M+73.9%	$42.86M+130%	$18.65M+5,094%
Interest paid	——	$8.84M0.0%	$8.84M0.0%	$8.84M0.0%	$8.84M0.0%
Accrued expenses and other liabilities	$17.48M-39.4%	$28.84M—	——	——	——
Increase (Decrease) in Prepaid Expense and Other Assets	$12.82M+58.1%	$8.1M—	——	——	——
Other Noncash Income (Expense)	——	——	——	——	-$6.34M+23.4%
Payment for (Proceeds from) Other Investing Activity	$321K-20.5%	$404K+1,654%	-$26K-13.0%	-$23K-119%	$123K+208%
Payments to Acquire Intangible Assets	$68.55M+17.9%	$58.16M+19.8%	$48.56M+16.4%	$41.71M+0.4%	$41.53M+14.7%
Proceeds From Sale And Maturity Of Available For Sale Securities	$319.22M-1.4%	$323.6M+9.2%	$296.22M+21.4%	$243.92M-9.0%	$268.13M-17.8%
Accrued royalty in excess of minimum payable to the sellers of Thiola	——	$14.28M-2.0%	$14.57M-1.9%	$14.86M-1.9%	$15.15M-1.9%
Operating Lease Payments	——	$6.58M+0.7%	$6.53M+0.7%	$6.49M+0.7%	$6.44M+0.7%
Payment Of Guaranteed Minimum Royalty	$2.1M0.0%	$2.1M0.0%	$2.1M0.0%	$2.1M0.0%	$2.1M0.0%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Travere Therapeutics, Inc.'s cash flow data come from?: Every line is extracted from Travere Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.